Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Stent Clinical Trials

A listing of Stent medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (48) clinical trials

Korean Multicenter Registry of INNOVA Stent for Femoropopliteal Artery Disease: (K-INNOVA Registry)

Prospective, single-arm, multi-center registry study A total of 150 subjects with femoropopliteal artery disease who meet all inclusion and exclusion criteria will be included. Patients will be followed clinically for 12 months after the procedure. Duplex ultrasound, CT or catheter-based angiography follow-up according to participating hospital's protocol will be performed ...

Phase N/A

DRUG ELUTING STENT FOR DIABETIC PATIENTS IN CORONARY ARTERY DISEASE TREATMENT

DEDICATE Registry: DRUG ELUTING STENT FOR DIABETIC PATIENTS IN CORONARY ARTERY DISEASE TREATMENT A POST MARKET REGISTRY OF ABLUMINUS SIROLIMUS ELUTING CORONARY STENT SYSTEM FOR PERCUTANEOUS INTERVENTION IN PATIENTS WITH DIABETES MELLITUS Version 1.0 Principal Investigator Dr. Luca Testa, MD, PhD Head of Coronary Revascularization Unit Head of Clinical Research ...

Phase N/A

Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft

In this study, patients will be observed who receive an E-liac Stent Graft for treatment of isolated iliac aneurysms or an E-liac Stent Graft in combination with one of the following AAA stent grafts: E-tegra Stent Graft, Endurant AAA Stent Graft, Zenith AAA Endovascular Graft, Gore Excluder AAA Endoprosthesis for ...

Phase N/A

E-tegra Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms

The purpose of this study is to evaluate clinical and technical success as well as safety and feasibility of the E-tegra Stent Graft System used in endovascular treatment of infrarenal aortic aneurysm.

Phase N/A

Real World Drug-Eluting Stent Prospective Open Multi-site Registry in Korea: BioMimeTM Stent Ultimaster Stent vs. Xience Stent By SMart Angioplastry Research Team (SMARTDESK-MX)

A prospective, open, multicenter, and observational study will register and compare Xience groups treated in institutions such as the BioMime , Ultimaster group prospectively registered from June 2016. The Xience group has already been registered in the previous study (SMARTDESK-BX), so BioMimeTM and Ultimaster only need to be registered. Follow-up ...

Phase N/A

Effect and Efficacy of Xpedition /Alpine Everolimus-eluting Stent for Coronary Atherosclerosis

Secondary endpoints of this study are Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI Target vessl failure Composite rate of cardiac death and any MI, 3 years Composite rate of all death and any MI Composite rate of all death, any MI, ...

Phase N/A

BIOFLOW-III UK Satellite Registry Orsiro Stent System

For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success. However, the medium to long-term complications range from rather immediate elastic coil or vessel contraction to longer processes like smooth muscle cell proliferation and excessive production of extra cellular matrix, ...

Phase N/A

Effect and Efficacy of Onyx Zotarolimus-eluting Stent for Coronary Atherosclerosis

Secondary endpoints are Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI (percutaneous coronary intervention), Target vessel failure Composite rate of cardiac death and any MI, 3 years Composite rate of all death and any MI Composite rate of all death, any MI, ...

Phase N/A

3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation

To evaluate safety of reduction of dual antiplatelet therapy period to three months after implantation of Ultimaster sirolimus-eluting stent (U-SES). Additionally to investigate appropriateness of thienopyridine monotherapy with discontinuation of aspirin.

Phase N/A

Bern Venous Stent Registry

Background: Obstruction and stenosis of the ilio-femoro-caval veins are difficult to treat by conservative measures only. Despite anticoagulation and consequent use of compression stockings, lower extremity venous hypertension affects patients quality of life and health status by causing venous claudication, swelling, skin changes, and venous ulcers. In the last decades ...

Phase N/A